

## 5.2 Hepatitis infections

### 5.2a Chronic hepatitis B

**Other drugs used for Chronic hepatitis B** Interferon alfa, p. 577 · Lamivudine, p. 436 · Tenofovir disoproxil, p. 437

#### ANTIVIRALS > NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS

F 431

26-Feb-2018

### Tenofovir alafenamide

#### ● INDICATIONS AND DOSE

##### Chronic hepatitis B (initiated by a specialist)

###### ► BY MOUTH

- Child 12–17 years (body-weight 35 kg and above): 25 mg once daily (for duration of treatment consult product literature)

- **CAUTIONS** Decompensated liver disease · HIV co-infection
- **INTERACTIONS** → Appendix 1: tenofovir alafenamide
- **SIDE-EFFECTS**
- Common or very common Abdominal distension
- Frequency not known Hepatitis aggravated (during or following treatment)
- **BREAST FEEDING** Manufacturer advises avoid—present in milk in *animal* studies.
- **HEPATIC IMPAIRMENT** Manufacturer advises caution in decompensated hepatic disease (no information available).
- **PRE-TREATMENT SCREENING** Manufacturer advises HIV antibody testing should be offered to those with unknown HIV-1 status before initiation of treatment.
- **MONITORING REQUIREMENTS** Manufacturer advises monitor liver function tests at repeated intervals during treatment and for at least 6 months after last dose—recurrent hepatitis may occur on discontinuation.
- **PATIENT AND CARER ADVICE**
- Missed doses** Manufacturer advises if a dose is more than 18 hours late, the missed dose should not be taken and the next dose should be taken at the normal time.

- **MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug.

#### Tablet

##### CAUTIONARY AND ADVISORY LABELS 21

- **Vemlidy** (Gilead Sciences International Ltd) ▼  
Tenofovir alafenamide (as Tenofovir alafenamide fumarate)  
25 mg Vemlidy 25mg tablets | 30 tablet [POM] £325.73

### 5.2b Chronic hepatitis C

**Other drugs used for Chronic hepatitis C** Interferon alfa, p. 577 · Peginterferon alfa, p. 419

#### ANTIVIRALS > NUCLEOSIDE ANALOGUES

### Ribavirin

#### (Tribavirin)

#### ● INDICATIONS AND DOSE

##### Bronchiolitis

- BY INHALATION OF AEROSOL, OR BY INHALATION OF NEBULISED SOLUTION
- Child 1–23 months: Inhale a solution containing 20 mg/mL for 12–18 hours for at least 3 days, maximum

of 7 days, to be administered via small particle aerosol generator

#### Life-threatening RSV, parainfluenza virus, and adenovirus infection in immunocompromised children (administered on expert advice)

##### ► BY INTRAVENOUS INFUSION

- Child: 33 mg/kg for 1 dose, to be administered over 15 minutes, then 16 mg/kg every 6 hours for 4 days, then 8 mg/kg every 8 hours for 3 days

##### REBETOL<sup>®</sup> CAPSULES

#### Chronic hepatitis C (in combination with interferon alfa or peginterferon alfa) in previously untreated children without liver decompensation

##### ► BY MOUTH

- Child 3–17 years (body-weight up to 47 kg): 15 mg/kg daily in 2 divided doses
- Child 3–17 years (body-weight 47–49 kg): 200 mg, dose to be given in the morning and 400 mg, dose to be given in the evening
- Child 3–17 years (body-weight 50–64 kg): 400 mg twice daily
- Child 3–17 years (body-weight 65–80 kg): 400 mg, dose to be given in the morning and 600 mg, dose to be given in the evening
- Child 3–17 years (body-weight 81–104 kg): 600 mg twice daily
- Child 3–17 years (body-weight 105 kg and above): 600 mg, dose to be given in the morning and 800 mg, dose to be given in the evening

##### REBETOL<sup>®</sup> ORAL SOLUTION

#### Chronic hepatitis C (in combination with interferon alfa or peginterferon alfa) in previously untreated children without liver decompensation

##### ► BY MOUTH

- Child 3–17 years (body-weight up to 47 kg): 15 mg/kg daily in 2 divided doses
- Child 3–17 years (body-weight 47–49 kg): 200 mg, dose to be given in the morning and 400 mg, dose to be given in the evening
- Child 3–17 years (body-weight 50–64 kg): 400 mg twice daily
- Child 3–17 years (body-weight 65–80 kg): 400 mg, dose to be given in the morning and 600 mg, dose to be given in the evening
- Child 3–17 years (body-weight 81–104 kg): 600 mg twice daily
- Child 3–17 years (body-weight 105 kg and above): 600 mg, dose to be given in the morning and 800 mg, dose to be given in the evening

#### ● UNLICENSED USE

- When used by inhalation Inhalation licensed for use in children (age range not specified by manufacturer).
- With intravenous use Intravenous preparation not licensed.

#### ● CONTRA-INDICATIONS

- With systemic use Active severe psychiatric condition · autoimmune disease · autoimmune hepatitis · consult product literature for specific contra-indications when ribavirin used in combination with other medicinal products · haemoglobinopathies · history of severe psychiatric condition · severe debilitating medical conditions · severe, uncontrolled cardiac disease in children with chronic hepatitis C

#### ● CAUTIONS

- When used by inhalation maintain standard supportive respiratory and fluid management therapy
- With systemic use cardiac disease (assessment including ECG recommended before and during treatment—discontinue if deterioration) · consult product literature for specific cautions when ribavirin used in combination with other medicinal products · patients with a